Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer
Abstract Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing 18F-rhPSMA-7 or 18F-flot...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83074-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594781540188160 |
|---|---|
| author | Marco M. E. Vogel Isabel Rauscher Jürgen E. Gschwend Türkay Hekimsoy Nicola Gabler Charlotte Olufs Calogero D’Alessandria Jan C. Peeken Stephanie E. Combs Matthias Eiber |
| author_facet | Marco M. E. Vogel Isabel Rauscher Jürgen E. Gschwend Türkay Hekimsoy Nicola Gabler Charlotte Olufs Calogero D’Alessandria Jan C. Peeken Stephanie E. Combs Matthias Eiber |
| author_sort | Marco M. E. Vogel |
| collection | DOAJ |
| description | Abstract Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing 18F-rhPSMA-7 or 18F-flotufolastat (18F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET. We evaluated biochemical failure-free survival (bFS) and overall rates of bFS in 110 evaluable patients with recurrent PC after radical prostatectomy who received SRT. 82 patients received 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT and 28 received C-SRT. Median bFS for patients with 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT was not reached while median bFS was 45.6 months for patients with C-SRT (p = 0.101). %bFS were 95% (52/55) vs 87% (20/23), 90% (27/30) vs 75% (15/20), 89% (16/18) vs 68% (13/19) and 100% (3/3) vs 57% (8/14) for PET-guided vs C-SRT at 12, 24, 36, and 48 months, respectively. Among patients treated in the prostate bed only, median bFS was not reached for PSMA-PET-guided SRT (n = 52) vs 55.1 months in the C-SRT group (n = 25; p = 0.063). %bFS was greater for PSMA-PET-guided SRT than C-SRT at all evaluated timepoints. 18F-rhPSMA-7/18F-flotufolastat-guided SRT yielded favorable disease outcomes. Although statistical significance was not reached, likely due to the limited sample size in this preliminary analysis, our data illustrate potential for 18F-flotufolastat-PET-guided SRT. |
| format | Article |
| id | doaj-art-982da70e1c004ef39cda5001dca593e4 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-982da70e1c004ef39cda5001dca593e42025-01-19T12:19:58ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-024-83074-3Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancerMarco M. E. Vogel0Isabel Rauscher1Jürgen E. Gschwend2Türkay Hekimsoy3Nicola Gabler4Charlotte Olufs5Calogero D’Alessandria6Jan C. Peeken7Stephanie E. Combs8Matthias Eiber9Department of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Urology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM)Abstract Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing 18F-rhPSMA-7 or 18F-flotufolastat (18F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET. We evaluated biochemical failure-free survival (bFS) and overall rates of bFS in 110 evaluable patients with recurrent PC after radical prostatectomy who received SRT. 82 patients received 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT and 28 received C-SRT. Median bFS for patients with 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT was not reached while median bFS was 45.6 months for patients with C-SRT (p = 0.101). %bFS were 95% (52/55) vs 87% (20/23), 90% (27/30) vs 75% (15/20), 89% (16/18) vs 68% (13/19) and 100% (3/3) vs 57% (8/14) for PET-guided vs C-SRT at 12, 24, 36, and 48 months, respectively. Among patients treated in the prostate bed only, median bFS was not reached for PSMA-PET-guided SRT (n = 52) vs 55.1 months in the C-SRT group (n = 25; p = 0.063). %bFS was greater for PSMA-PET-guided SRT than C-SRT at all evaluated timepoints. 18F-rhPSMA-7/18F-flotufolastat-guided SRT yielded favorable disease outcomes. Although statistical significance was not reached, likely due to the limited sample size in this preliminary analysis, our data illustrate potential for 18F-flotufolastat-PET-guided SRT.https://doi.org/10.1038/s41598-024-83074-3Prostate cancerPSMA-PET18F-rhPSMA-718F-flotufolastatSalvage radiotherapy |
| spellingShingle | Marco M. E. Vogel Isabel Rauscher Jürgen E. Gschwend Türkay Hekimsoy Nicola Gabler Charlotte Olufs Calogero D’Alessandria Jan C. Peeken Stephanie E. Combs Matthias Eiber Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer Scientific Reports Prostate cancer PSMA-PET 18F-rhPSMA-7 18F-flotufolastat Salvage radiotherapy |
| title | Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer |
| title_full | Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer |
| title_fullStr | Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer |
| title_full_unstemmed | Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer |
| title_short | Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer |
| title_sort | biochemical failure free survival of 18f rhpsma 7 and 18f flotufolastat pet guided salvage radiotherapy for patients with recurrent prostate cancer |
| topic | Prostate cancer PSMA-PET 18F-rhPSMA-7 18F-flotufolastat Salvage radiotherapy |
| url | https://doi.org/10.1038/s41598-024-83074-3 |
| work_keys_str_mv | AT marcomevogel biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT isabelrauscher biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT jurgenegschwend biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT turkayhekimsoy biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT nicolagabler biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT charlotteolufs biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT calogerodalessandria biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT jancpeeken biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT stephanieecombs biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer AT matthiaseiber biochemicalfailurefreesurvivalof18frhpsma7and18fflotufolastatpetguidedsalvageradiotherapyforpatientswithrecurrentprostatecancer |